ZA944980B - Pharmaceutical combination - Google Patents

Pharmaceutical combination

Info

Publication number
ZA944980B
ZA944980B ZA944980A ZA944980A ZA944980B ZA 944980 B ZA944980 B ZA 944980B ZA 944980 A ZA944980 A ZA 944980A ZA 944980 A ZA944980 A ZA 944980A ZA 944980 B ZA944980 B ZA 944980B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical combination
inhibitor
products
sequelae
renin
Prior art date
Application number
ZA944980A
Other languages
English (en)
Inventor
Jean-Paul Clozel
Martine Clozel
Wolfgang Osterrieder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA944980B publication Critical patent/ZA944980B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA944980A 1993-07-15 1994-07-08 Pharmaceutical combination ZA944980B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH213193 1993-07-15

Publications (1)

Publication Number Publication Date
ZA944980B true ZA944980B (en) 1995-02-06

Family

ID=4226611

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA944980A ZA944980B (en) 1993-07-15 1994-07-08 Pharmaceutical combination

Country Status (25)

Country Link
US (1) US5696116A (fr)
EP (1) EP0634175B1 (fr)
JP (1) JP2746537B2 (fr)
KR (1) KR100370181B1 (fr)
CN (1) CN1105573C (fr)
AT (1) ATE198551T1 (fr)
AU (1) AU683262B2 (fr)
BR (1) BR9402815A (fr)
CA (1) CA2128142C (fr)
CZ (1) CZ285413B6 (fr)
DE (1) DE59409631D1 (fr)
DK (1) DK0634175T3 (fr)
ES (1) ES2154277T3 (fr)
GR (1) GR3035702T3 (fr)
HU (1) HU221202B1 (fr)
IL (1) IL110272A (fr)
NO (1) NO312578B1 (fr)
NZ (1) NZ260969A (fr)
PL (1) PL176445B1 (fr)
PT (1) PT634175E (fr)
RU (1) RU2146522C1 (fr)
SA (1) SA94150155B1 (fr)
TW (1) TW287949B (fr)
UA (1) UA27870C2 (fr)
ZA (1) ZA944980B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
JP2001523218A (ja) 1996-02-20 2001-11-20 ブリストル―マイヤーズ・スクイブ・カンパニー ビフェニルイソキサゾール・スルホンアミドの製造法
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU750755B2 (en) * 1997-09-26 2002-07-25 Abbvie Deutschland Gmbh & Co Kg Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
CN1234357C (zh) * 1998-07-10 2006-01-04 诺瓦提斯公司 缬沙坦和钙通道阻断剂的抗超敏组合
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
CN101011390A (zh) * 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
HUP0201320A2 (en) 1999-03-19 2002-08-28 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides and intermediates thereof
DE60131032T2 (de) * 2000-08-25 2008-08-14 Research Corp. Technologies, Inc., Tucson Verwendung von antikonvulsiven Aminosäure zur Behandlung von Migräne
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
PT1517682E (pt) * 2002-06-28 2007-02-28 Speedel Pharma Ag Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
CN1838957A (zh) * 2003-08-22 2006-09-27 舍林股份公司 抑制趋化因子的哌嗪衍生物及其治疗心肌炎的用途
CN101312962A (zh) * 2005-12-06 2008-11-26 参天制药株式会社 角膜结膜病变的治疗剂
EP2091539A1 (fr) * 2006-12-12 2009-08-26 Gilead Colorado, Inc. Utilisation de l'ambrisentan associé avec un inhibiteur de rénine dans les troubles de l'hypertension
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8071596B2 (en) 2007-01-12 2011-12-06 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
MA49664A (fr) 2017-02-27 2020-06-03 Idorsia Pharmaceuticals Ltd Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS559058A (en) * 1978-07-06 1980-01-22 Dainippon Pharmaceut Co Ltd 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4470972A (en) * 1981-04-28 1984-09-11 Schering Corporation 7-Carboxyalkylaminoacyl-1,4-dithia-7-azaspiro[4.4]-nonane-8-carboxylic acids
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
AT377496B (de) * 1981-06-19 1985-03-25 Voith Gmbh J M Vorrichtung zum anwickeln einer warenbahn auf eine neu eingelegte wickelhuelse in einer doppeltragwalzen-wickelmaschine
US4410520A (en) * 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
GB2128984B (en) * 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
DE3542794A1 (de) * 1985-12-04 1987-06-11 Bayer Ag Antihypertensives kombinationspraeparat
DE58905990D1 (de) * 1988-03-24 1993-12-02 Hoffmann La Roche Antihypertensives Kombinationspräparat.
JPH06505474A (ja) * 1991-01-31 1994-06-23 アボツト・ラボラトリーズ エンドセリン転換酵素阻害剤
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
ATE156120T1 (de) * 1991-02-07 1997-08-15 Roussel Uclaf Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW216770B (fr) * 1991-07-23 1993-12-01 Hoffmann La Roche
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5420123A (en) * 1992-12-21 1995-05-30 Bristol-Myers Squibb Company Dibenzodiazepine endothelin antagonists

Also Published As

Publication number Publication date
PL304292A1 (en) 1995-01-23
DE59409631D1 (de) 2001-02-15
DK0634175T3 (da) 2001-04-30
RU94026283A (ru) 1996-05-20
ATE198551T1 (de) 2001-01-15
UA27870C2 (uk) 2000-10-16
NO942650D0 (no) 1994-07-14
CZ285413B6 (cs) 1999-08-11
CA2128142C (fr) 2007-03-06
HU221202B1 (en) 2002-08-28
NZ260969A (en) 1996-01-26
CZ167794A3 (en) 1995-01-18
AU683262B2 (en) 1997-11-06
RU2146522C1 (ru) 2000-03-20
JPH0753408A (ja) 1995-02-28
KR960013371A (ko) 1996-05-22
CN1105573C (zh) 2003-04-16
AU6735794A (en) 1995-01-27
PL176445B1 (pl) 1999-05-31
IL110272A0 (en) 1994-10-21
BR9402815A (pt) 1995-04-04
ES2154277T3 (es) 2001-04-01
EP0634175A1 (fr) 1995-01-18
CN1107364A (zh) 1995-08-30
CA2128142A1 (fr) 1995-01-16
KR100370181B1 (ko) 2003-04-26
NO942650L (no) 1995-01-16
US5696116A (en) 1997-12-09
HU9402064D0 (en) 1994-09-28
NO312578B1 (no) 2002-06-03
EP0634175B1 (fr) 2001-01-10
GR3035702T3 (en) 2001-07-31
JP2746537B2 (ja) 1998-05-06
SA94150155B1 (ar) 2005-11-15
IL110272A (en) 1998-07-15
PT634175E (pt) 2001-06-29
HUT67331A (en) 1995-03-28
TW287949B (fr) 1996-10-11

Similar Documents

Publication Publication Date Title
TW287949B (fr)
NO962162D0 (no) Dipeptider som bevirker frigjöring av veksthormon
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
EP0602757A3 (fr) Système pour l'application de noeuds en matière de matériel de suture chirurgical.
AU6257798A (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
IL127244A0 (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
CA2163361A1 (fr) Derives de substitution de guanidines, agents therapeutiques
GR3035526T3 (en) Retroviral protease inhibitors.
AU6452194A (en) Pharmaceutical agents for treatment of emesis
DE69838042D1 (de) Verwendung von Inhibitoren des Renin-Angiotensin Systems
WO1993000094A3 (fr) Utilisation de derives de tetrahydrobenzazepine pour le traitement de l'hypertension porte et de la migraine
EP0726072A3 (fr) Composition pour traiter l'hypertension ou l'insuffisance cardiaque contenant un antagoniste d'angiotensine II et un inhibiteur d'endopeptidase
GB9804886D0 (en) Therapeutic combination
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
AU4163793A (en) Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease
DE59810600D1 (de) Endothelin antagonist und renin-angiotensin system hemmer als kombinationspräparate
NZ331789A (en) Method of treating heart failure with non-peptide endothelin antagonists
CA2055948A1 (fr) Utilisation d'une combinaison d'un inhibiteur de l'enzyme de conversion de l'angiotensine et d'un antagoniste du calcium pour le traitement de la proteinurie
EP0604853A3 (en) Pharmaceutical composition for preventing or treating arteriosclerosis.
AU1506692A (en) Pharmaceutical compositions
EP0653208A3 (fr) Antagonistes de la substance P pour le traitement et la prévention de l'erythème solaire.
ZA200107523B (en) Method for improving the stability of stored and/or light-sensitive therapeutic systems or component thereof.
MX9302142A (es) Uso de 3r- y 3r,s-difenilmetoxi-1-(3,4-metileno-dioxifenetil)-piperidina y composicion que la contienen.
IL101540A0 (en) Method and composition for the treatment of herpes related disorders
ES2106098T3 (es) Lacidipino para el tratamiento de la arteriosclerosis.